HLB Pharmaceutical Co., Ltd. (KOSDAQ:047920)
South Korea flag South Korea · Delayed Price · Currency is KRW
18,360
-380 (-2.03%)
Jul 18, 2025, 3:30 PM KST

HLB Pharmaceutical Company Description

HLB Pharmaceutical Co., Ltd., a pharmaceutical company, researches and develops peptide drugs in South Korea.

The company offers skeletal muscle relaxants, tranquilizers, antihistamines, antihypertensive agents, pain relief, antipruritics, astringents, anti-inflammatories, alimentary system drugs, metabolic drugs, ophthalmic agents, local anesthetics, antiarteriosclerotic agents, expectorants, antipyretics, analgesics, antidiabetic drug, chemotherapeutics, peptic ulcer agents, central nervous system drug, antibiotics, digestives, antacids, dental drugs, multivitamins, parasistic skin disese drugs, dermatlogicals, agents for urogenital organ, amino acid agent, antitussive, mucolytic agents, anthelmintics, antidiarrheals, circulatory system drug, vitamins, skin softeners, anti-hemorrhoid drugs, and agents for liver disease.

It is also developing CTT-004 for the treatment of ataxia induced by spinocerebellar degeneration; and offers CMO services.

The company was formerly known as Mediforum Pharmaceutical Incorporation and changed its name to HLB Pharmaceutical Co., Ltd in October 2020.

HLB Pharmaceutical Co., Ltd. was founded in 1998 and is headquartered in Namyangju-si, South Korea.

HLB Pharmaceutical Co., Ltd.
CountrySouth Korea
Founded1998
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
CEOJae-Hyung Park

Contact Details

Address:
27, Gyeonggang-ro
Namyangju-si, 12244
South Korea
Phone82 3 1557 0001
Websitehlbpharma.co.kr

Stock Details

Ticker Symbol047920
ExchangeKOSDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyKRW
ISIN NumberKR7047920004
SIC Code2834

Key Executives

NamePosition
Jae-Hyung ParkChief Executive Officer